ERBB2 and breast carcinoma: Similarly, in 2011, Drezek et al. demonstrated that PTT specifically inhibited drug-resistant breast cancer cells (JIMT-1) in vitro by using HER2 monoclonal antibody-modified core/shell of SiO2/Au nanostructure34.